ConvaTec Group stock falls 1.4 percent as guidance holds

Published on 09/24/2026 at 23:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ConvaTec Group stock stood at GBp 211.60 on September 24, 2026, below its GBp 259.30 yearly high. July guidance called for 5-7 percent organic growth and a 23 percent margin.

Moderne Medizintechnik-Reinraumfertigung mit Technikern an steriler Produktionslinie — ConvaTec Group Plc GB00BD3VFW73 zeigt moderne Medizintechnik-Fertigung mit sterilen Produktionslinien und Reinraumtechnikern, Illustration mit AI erstellt.

ConvaTec Group (ISIN GB00BD3VFW73) stock stood at GBp 211.60 on the LSE on September 24, 2026, down 1.40 percent from the previous close. The price was 18.4 percent below the 52-week high of GBp 259.30, making the yearly range more important than the single-session move.

Guidance keeps growth measurable

In an update dated July 15, 2026, Scottish Widows reported that ConvaTec expected organic growth of 5-7 percent in 2026 and an adjusted operating margin of at least 23 percent. The same update said the company expected double-digit growth in adjusted earnings per share for the year.

That framework gives the stock a clear operating test. Revenue growth must reach the 5 percent floor while the margin stays at or above 23 percent, so execution rather than a broader market move is the key numerical checkpoint.

Kepler sets a GBp 286 target

Investing.com reported on August 27, 2026, that Kepler Cheuvreux began coverage with a Buy rating and a GBp 286 price target. That target stood 35.2 percent above the September 24 price, a material gap that depends on the company converting the guidance into repeatable earnings growth.

The company is a constituent of the FTSE 100, according to Investegate. Its products cover ostomy care, wound care, continence care and infusion, which gives the growth target several operating areas rather than a single product dependency.

Stock remains below its yearly high

ConvaTec Group had a market capitalization of GBP 4,124,941,687 as of September 24, 2026. The GBp 211.60 closing price on the LSE and the 1.40 percent daily decline place the shares closer to the lower half of the GBp 193.00 to GBp 259.30 52-week range than to its annual peak.

The combination of a 5-7 percent growth target, a 23 percent margin floor and a GBp 286 analyst target defines the next valuation debate. The September 24 price move shows that the market is still measuring delivery against those figures.